Education
About Us
Working with TipRanks
Follow Us
Avenue Therapeutics (ATXI)
:ATXI
ATXI Stock Chart & Stats
$0.73
-$0.12(-6.36%)
At close: 4:00 PM EST
$0.73
-$0.12(-6.36%)
Day’s Range― - ―
52-Week Range$0.17 - $2.45
Previous CloseN/A
Volume16.16K
Average Volume (3M)2.45K
Market Cap
$2.29M
Enterprise Value-$3.91M
Total Cash (Recent Filing)$3.33M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Nov 17, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding3,183,558
10 Day Avg. Volume2,286
30 Day Avg. Volume2,446
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-1.71
Enterprise Value/Revenue-2.79
Enterprise Value/Gross Profit-2.79
Enterprise Value/Ebitda0.60
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst maintains a Buy rating on the AJ201 opportunity.
Clinical MilestonesThe company is on track to get to its key milestone, the P2a data for AJ201 in Spinal Bulbar Muscular Atrophy, which is expected in the coming months.
Regulatory PathwayPositive data indicative of potential clinical improvement should pave the way to meet with the FDA to determine next steps.
Bears Say
Capital RequirementsThe company is going to need to raise capital soon, either before or after the data, given the short runway.
Financial PerformanceAvenue reported 2Q24 results with a net loss of ($2.7M) and ended the period with $4.9M in cash on the balance sheet.
Financing NeedsA P2a is planned, but additional financing is needed for which Avenue is exploring its options, including potential partnerships.
Avenue Therapeutics News
ATXI FAQ
What was Avenue Therapeutics’s price range in the past 12 months?
Avenue Therapeutics lowest stock price was $0.17 and its highest was $2.45 in the past 12 months.
What is Avenue Therapeutics’s market cap?
Avenue Therapeutics’s market cap is $2.29M.
When is Avenue Therapeutics’s upcoming earnings report date?
Avenue Therapeutics’s upcoming earnings report date is Nov 17, 2025 which is in 13 days.
How were Avenue Therapeutics’s earnings last quarter?
Avenue Therapeutics released its earnings results on Aug 18, 2025. The company reported $0.105 earnings per share for the quarter, beating the consensus estimate of N/A by $0.105.
Is Avenue Therapeutics overvalued?
According to Wall Street analysts Avenue Therapeutics’s price is currently Overvalued.
Does Avenue Therapeutics pay dividends?
Avenue Therapeutics does not currently pay dividends.
What is Avenue Therapeutics’s EPS estimate?
Avenue Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avenue Therapeutics have?
Avenue Therapeutics has 3,183,558 shares outstanding.
What happened to Avenue Therapeutics’s price movement after its last earnings report?
Avenue Therapeutics reported an EPS of $0.105 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.754%.
Which hedge fund is a major shareholder of Avenue Therapeutics?
Currently, no hedge funds are holding shares in ATXI
Company Description
Avenue Therapeutics
Avenue Therapeutics (ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases. The company's core product includes intravenous (IV) tramadol, which is designed to treat moderate to moderately severe postoperative pain. Avenue Therapeutics operates within the healthcare sector, with a focus on pain management solutions.
Technical Analysis
Biodexa Pharmaceuticals
―
Q/C Technologies
―
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
Oragenics
―
Ownership Overview
10.34% Insiders
5.69% Other Institutional Investors
83.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---